Evidence map›Paper›PMID 40606751›Full record

ArticleiScience2025

Hypoimmune CD19 CAR T cells treat allogeneic mice with features of spontaneous systemic lupus erythematosus.

Xiaomeng Hu, Kathy White, Ari G Olroyd, Annabelle Friera, Chenyan Wang, Carolin B Caruso, Andrew J Connolly, Tobias Deuse, Sonja Schrepfer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaomeng HuSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Kathy WhiteSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Ari G OlroydSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Annabelle FrieraSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Chenyan WangSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Carolin B CarusoSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Andrew J ConnollyDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Tobias DeuseDepartment of Surgery, Division of Cardiothoracic Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California, San Francisco, San Francisco, CA, USA.
Sonja SchrepferSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoimmune (HIP) MHC class I- and II-deficient and CD47-overexpressing CD19 CAR T cells were generated and tested in an allogeneic NZB/W mouse model of spontaneous systemic lupus erythematosus with established disease. HIP CAR T cells showed persistent engraftment, achieved lasting deep tissue B cell depletion, diminished antibody levels and systemic pro-inflammatory cytokine levels, mitigated proteinuria and glucosuria, alleviated structural kidney injury, and improved survival after 21 weeks. HIP CAR T cells did not induce any immune activation in this fully allogeneic model and thus completely escaped allorejection. In contrast, MHC-replete, non-HIP-edited wild-type (WT) CD19 CAR T cells induced a strong adaptive immune response and vanished quickly without inducing meaningful B cell depletion and without improving disease markers or survival. Conditioning of NZB/W mice with irradiation did not enhance the HIP CAR T cell efficacy and might hint at their potency for autoimmune patients without prior lymphodepletion.

Indexed as

Immune responseImmunology

Identifiers

PMID40606751
PMCPMC12221509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.